RDEA3170 Monotherapy in Subjects With Gout

Inclusion Criteria: * Subject meets the diagnosis of gout per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout. * Subject has a serum urate level ≥ 6.5 mg/dL and ≤ 10.0 mg/dL during the Screening Period. * Subject has a body mass index \< 40 kg/m2. Exclusion Criteria: * Subject is pregnant or breastfeeding. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz \[150 mL\] of wine, 12 oz \[360 mL\] of beer, or 1.5 oz \[45 mL\] of hard liquor). * Subject has a history or suspicion of kidney stones. * Subject has a history or suspicion of drug abuse within the past 5 years. * Subject has a history of symptomatic myositis/myopathy or rhabdomyolysis. * Subject has a known or suspected human immunodeficiency virus infection. * Subject has a positive test for active hepatitis B or hepatitis C infection. * Subject has a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ Grade 1 cervical cancer. * Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants. * Subject has a QT interval corrected for heart rate according to Fridericia's formula \> 450 msec during the Screening Period, confirmed by a repeat assessment. * Subject has uncontrolled hypertension. * Subject has an estimated creatinine clearance \< 60 mL/min. * Subject has an alkaline phosphatase \> 2.0 x upper limit of normal during the Screening Period. * Subject has active liver disease or impaired hepatic function. * Subject is receiving chronic treatment with more than 325 mg salicylates per day. * Subject has a medical condition that requires or may require systemic immunosuppressive (eg, chronic low-dose oral prednisone) or immunomodulatory treatment. * Subject is unable to take colchicine for gout flare prophylaxis. * Subject is receiving strong or moderate CYP3A inhibitors, p-glycoprotein inhibitors, or digoxin. * Subject received any strong enzyme- inducing drug or product (eg, rifampin, rifabutin, phenytoin, phenobarbital, St. John's Wort) within 2 months prior to Day 1 or refuses to refrain from taking these medications until the end of the study. * Subject received an investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to the Screening Period. * Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.